A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

These data indicate that "prolonged [TNF inhibitor] treatment plays a protective role in PsA development in severe psoriasis ...

Company News Published 07/02/2025, 07:49 AM 0 FDA partially lifts clinical hold on VYNE’s VYN202 psoriasis trial VYNE -5.63% ...

Those include having a Psoriasis Area and Severity Index (PASI) of 10 or more – indicating that lesions cover at least 10% of their body – and a Dermatology Life Quality Index (DLQI) score ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

New Treatment Option for Psoriasis Discovered Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria.